Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer

PARP inhibitors target BRCA mutations and defective homologous recombination repair (HRR) for the treatment of epithelial ovarian cancer (EOC). However, the treatment of HRR-proficient EOC with PARP inhibitors remains challenging. The objective of this study was to determine whether the combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Z. Ping, Zhu, Yong-Lian, Lo, Ying-Chun, Moscarelli, Jake, Xiong, Amy, Korayem, Yasmin, Huang, Pamela H., Giri, Smith, LoRusso, Patricia, Ratner, Elena S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239325/
https://www.ncbi.nlm.nih.gov/pubmed/30444904
http://dx.doi.org/10.1371/journal.pone.0207399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239325/
https://www.ncbi.nlm.nih.gov/pubmed/30444904
http://dx.doi.org/10.1371/journal.pone.0207399

Ejemplares similares